[Comparison of thiamazole pharmacokinetics in healthy individuals and patients with hyperthyroidism].
Pharmacokinetic parameters of thiamazole in hyperthyroid patients (40 subjects with Graves-Basedow disease--32 female and 8 male patients) and in healthy individuals (8 subjects--5 women and 3 men) were compared. A one-compartment model was used for the analysis of examined pharmacokinetic parameters. Area under thiamazole concentration curve (AUC) and thiamazole peak plasma concentration (cmax) were significantly decreased in hyperthyroid patients in comparison with healthy individuals. An analysis of other pharmacokinetic parameters suggests that observed differences seem to depend upon lowered and retarded thiamazole absorption from the gut and acceleration of drug metabolism in hepatic microsomal system in hyperthyroid patients.
Syrenicz
A
A
Kliniki Endokrynologii i Chorób Przemiany Materii PAM w Szczecinie.
Gawrońska-Szklarz
B
B
Wójcicki
J
J
Czekalski
S
S
D000328:Adult; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008713:Methimazole / Q000493:pharmacokinetics*; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D012016:Reference Values
D008713:Methimazole
Porównanie farmakokinetyki tiamazolu u osób zdrowych i chorych na nadczynność tarczycy.